1. Scrip
  2. >>R&D
  3. >>Clinical Trials

J&J’s Rybrevant/Lazcluze MARIPOSA Update Shows Greater Gains Over Tagrisso

Subcutaneous Rybrevant Data Reinforce Safety, Convenience

 
• By Mandy Jackson

Survival and other benefits with J&J’s EGFR/MET inhibitor Rybrevant plus EGFR inhibitor Lazcluze relative to AstraZeneca’s Tagrisso in first-line EGFR-mutant NSCLC continued to improve at 31.1 months.

3d rendered, medically accurate illustration of lung cancer. showing presence of cancerous tumor inside the lungs
Rybrevant plus Lazcluze efficacy continued to separate from Tagrisso monotherapy • Source: Shutterstock

Johnson & Johnson has evidence that the benefits of dual treatment with the firm’s EGFR/MET inhibitor Rybrevant (amivantamab) and EGFR inhibitor Lazcluze (lazertinib) improve over time from updated results from the Phase III MARIPOSA clinical trial of the two-drug combination versus AstraZeneca PLC’s standard-of-care EGFR inhibitor Tagrisso (osimertinib) in first-line non-small cell lung cancer (NSCLC) with EGFR mutations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

Pipeline Watch: Eight Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

More from R&D

Pipeline Watch: Eight Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

 
• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.